Pierre Fabre Medicament

Privately held: no public share price · France

Assets

(7 total)
7Total Assets
3Approved
0Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Approved
MEK1/2Small molecule
Non-Small Cell Lung CancerMelanoma
Approved
BRAF V600ESmall molecule
Non-Small Cell Lung CancerColorectal CancerMelanoma
Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer
Approved
EGFR/HER2Small molecule
Non-Small Cell Lung CancerBreast Cancer
HER2-Positive Breast Cancer
Phase 1/2
EGFR/HER2Small molecule
Non-Small Cell Lung Cancer
Phase 1/2
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
METMonoclonal antibody
Non-Small Cell Lung Cancer
Phase 1
RAFSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Binimetinib + EncorafenibPhase 3Melanoma
Est. primary completion 2027-03-31 · NCT05270044 · CT.gov ↗
What to watch
November 2027 (1)
STX-241Phase 1/2Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-11-20 · NCT06567015 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
ElticertinibPhase 1/2Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Est. primary completion 2029-12-01 · NCT06043817 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
VERT-002Phase 1/2Solid Tumor, MET Alteration
Est. primary completion 2030-10-21 · NCT06669117 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.